Stock Research for IRWD

IRWD

Featured Broker: Ally Invest

Get the due diligence for another stock.

 

IRWD Stock Chart & Research Data

The IRWD chart settings shown below allow you to select time intervals of 1 min, 30 mins, an hour or by day - week - month. There is also the ability to change the IRWD chart style to candles, hollow candles, bars, lines or add various indicators. You can even add a symbol and compare history.


 


IRWD Due diligence Resources & Stock Charts

The IRWD stock resources shown below were gathered to cut back on time by allowing you to visit multiple sites at once. For your convenience each link clicked will open in a window. In addition to the individual links there is a button at the bottom that will allow you to open all the links at the same time. Note opening all links at once may not work with all browsers. Some browsers block multiple windows, to resolve this please allow that site to use pop-ups.

The Four Most Popular Resources

CNN View IRWD Detailed Price Forecast - CNN Money CNN View IRWD Detailed Summary - Google Finance
Yahoo View IRWD Detailed Summary - Yahoo! Finance Zacks View IRWD Stock Research & Analysis - Zacks.com

Stock Analysis

TradeIdeas View IRWD Trends & Analysis - Trade-Ideas Barrons View IRWD Major Holders - Barrons
NASDAQ View IRWD Call Transcripts - NASDAQ Seeking View IRWD Breaking News & Analysis - Seeking Alpha
Spotlight View IRWD Annual Report - CompanySpotlight.com OTC Report View IRWD OTC Short Report - OTCShortReport.com
TradeKing View IRWD Fundamentals - TradeKing Charts View IRWD SEC Filings - Bar Chart
WSJ View Historical Prices for IRWD - The WSJ Morningstar View Performance/Total Return for IRWD - Morningstar
MarketWatch View the Analyst Estimates for IRWD - MarketWatch CNBC View the Earnings History for IRWD - CNBC
StockMarketWatch View the IRWD Earnings - StockMarketWatch MacroAxis View IRWD Buy or Sell Recommendations - MacroAxis
Bullish View the IRWD Bullish Patterns - American Bulls Short Pains View IRWD Short Pain Metrics - ShortPainBot.com

Social Media Mentions

StockTwits View IRWD Stock Mentions - StockTwits PennyStocks View IRWD Stock Mentions - PennyStockTweets
Twitter View IRWD Stock Mentions - Twitter Invest Hub View IRWD Investment Forum News - Investor Hub
Yahoo View IRWD Stock Mentions - Yahoo! Message Board Seeking Alpha View IRWD Stock Mentions - Seeking Alpha


Financial & Transaction Holdings

SECform4 View Insider Transactions for IRWD - SECform4.com Insider Cow View Insider Transactions for IRWD - Insider Cow
CNBC View IRWD Major Holdings Summary - CNBC OTC Markets View Insider Disclosure for IRWD - OTC Markets
Yahoo View Insider Transactions for IRWD - Yahoo! Finance NASDAQ View Institutional Holdings for IRWD - NASDAQ


Stock Charts

FinViz View IRWD Stock Insight & Charts - FinViz.com StockCharts View IRWD Investment Charts - StockCharts.com
BarChart View IRWD Stock Overview & Charts - BarChart Trading View View IRWD User Generated Charts - Trading View




Latest Financial News for IRWD


Most Analysts Are Bullish on Nektar Stock
Posted on Monday November 12, 2018

In November 2018, of the total ten analysts covering Nektar Therapeutics (NKTR), eight analysts have given the stock a “buy” or higher rating, and two analysts have given it a “hold” rating. The mean rating for Nektar Therapeutics stock is 1.8 with a target price of $88.5, implying an upside potential of 160.1% over Nektar Therapeutics’ trading price of $34.03 on November 10.


Analyzing Nektar Therapeutics’ Q3 Operational Performance
Posted on Monday November 12, 2018

Nektar Therapeutics (NKTR) incurred general and administrative expenses of $18.72 million in the third quarter of 2018 as compared with $12.06 million in the third quarter of 2017. Nektar Therapeutics expects general and administrative expenses in fiscal 2018 to be higher than they were in fiscal 2017.


How Nektar Therapeutics’ Gross Margin Trended
Posted on Monday November 12, 2018

Nektar Therapeutics’ (NKTR) non-cash royalty revenue associated with the sale of future royalties increased from $8.07 million in the third quarter of 2017 to $8.37 million in the third quarter of 2018. The significant drop in Nektar’s total revenues was attributable to a decline in license, collaboration, and other revenues, which decreased from $131.11 million in the third quarter of 2017 to $4.87 million in the third quarter of 2018.


See what the IHS Markit Score report has to say about Ironwood Pharmaceuticals Inc.
Posted on Monday November 12, 2018

Ironwood Pharmaceuticals Inc NASDAQ/NGS:IRWD


Stock Market & Investing Books

Enter a stock symbol to view the stock details.